In Vitro and in Vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5023-5030

  Mascio, Carmela T M ^a   Mortin, Lawrence I ^a   Howland, Karen T ^a   Van Praagh, Andrew D G ^a,b   Zhang, Shuxin ^a   Arya, Anu ^a   Chuong, Cun Lan ^a   Kang, Chunfeng ^a   Li, Tongchuan ^a   Silverman, Jared A ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

^b Carestream Molecular Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CB 183315; DAPTOMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; FLOW CYTOMETRY; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; MEMBRANE POTENTIAL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CRICETINAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; LIPOPEPTIDES; MALE; MESOCRICETUS; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; VANCOMYCIN;

EID: 84866313208     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00057-12     Document Type: Article

References (29)

1. Al-Nassir WN, et al. 2008. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin. Infect. Dis. 47:56-62. (Pubitemid 351920588)
2. Bartlett JG. 2007. Clostridium difficile: old and new observations. J. Clin. Gastroenterol. 41(Suppl 1):S24-S29. (Pubitemid 46626022)
3. Bartlett JG, Onderdonk AB, Cisneros RL, Kasper DL. 1977. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J. Infect. Dis. 136:701-705. (Pubitemid 8223685)
4. Chesnel L, et al. 2012. Treatment of CDAD with oral CB-183 315: time to recurrence, relapse and re-infection rates compared with vancomycin. Clin. Microbiol. Infect. 18(Suppl 3):380.
5. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrob. Agents Chemother. 56:1613-1615.
6. Cloud J, Kelly CP. 2007. Update on Clostridium difficile associated disease. Curr. Opin. Gastroenterol. 23:4-9. (Pubitemid 44875902)
7. Cohen SH, et al. 2010. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect. Control Hosp. Epidemiol. 31:431-455.
8. Collett D. 1994. Modeling survival data in medical research. Chapman and Hall, London, United Kingdom.
9. Craig WA, Gudmundsson S. 1996. Postantibiotic effect, p 296-329. In Lorian V (ed), Antibiotics in laboratory medicine, 4th ed Williams &Wilkins, Baltimore, MD.
10. Dallal RM, et al. 2002. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann. Surg. 235: 363-372. (Pubitemid 34183887)
11. Freeman J, Baines SD, Jabes D, Wilcox MH. 2005. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J. Antimicrob. Chemother. 56:717-725. (Pubitemid 41487774)
12. Johnson AP. 2010. New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile. Expert. Opin. Ther. Patents 20:1389-1399.
13. Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc. 53:457-481.
14. Kelly CP, Pothoulakis C, LaMont JT. 1994. Clostridium difficile colitis. N. Engl. J. Med. 330:257-262. (Pubitemid 24034138)
15. Lawrence SJ, Dubberke ER, Johnson S, Gerding DN. 2007. Clostridium difficile-associated disease treatment response depends on definition of cure. Clin. Infect. Dis. 45:1648-1651.
16. Louie TJ, et al. 2011. Fidaxomicin versus vancomycin for Clostridium difficile infection. N. Engl. J. Med. 364:422-431.
17. McDonald LC, Owings M, Jernigan DB. 2006. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerging Infect. Dis. 12:409-415.
18. Mullane KM, Gorbach S. 2011. Fidaxomicin: first-in-class macrocyclic antibiotic. Expert Rev. Anti-infect. Ther. 9:767-777.
19. Nelson RL, et al. 2011. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst. Rev. 7:CD004610. doi:10.1002/14651858.CD004610.pub4.
20. Novo D, Perlmutter NG, Hunt RH, Shapiro HM. 1999. Accurate flow cytometric membrane potential measurement in bacteria using diethyloxacarbocyanine and a ratiometric technique. Cytometry 35:55-63. (Pubitemid 29031192)
21. Patino H, et al. 2011. Efficacy and safety of the lipopeptide CB-183,315 for the treatment of Clostridium difficile infection, abstr. K-205a. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., September 17-20, Chicago, IL.
22. Razaq N, et al. 2007. Infection of hamsters with historical and epidemic BI types of Clostridium difficile. J. Infect. Dis. 196:1813-1819. (Pubitemid 351411942)
23. Shah D, Dang MD, Hasbun R, Koo HL, Jiang DuPont Z-DHL, Garey KW. 2010. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev. Anti-infect. Ther. 8:555-564.
24. Silverman JA, Oliver N, Andrew T, Li T. 2001. Resistance studies with daptomycin. Antimicrob. Agents Chemother. 45:1799-1802. (Pubitemid 32466351)
25. Silverman JA, Perlmutter NG, Shapiro HM. 2003. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob. Agents Chemother. 47:2538-2544. (Pubitemid 36919456)
26. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother. 56:3448-3452.
27. Swanson RN, et al. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob. Agents Chemother. 35: 1108-1111.
28. Tyrrell KL, et al. 2006. In vitro activities of daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob. Agents Chemother. 50:2728-2731. (Pubitemid 44198694)
29. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. 2007. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. Dis. 45: 302-307. (Pubitemid 47101025)